Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers CL, Flavell RA, Wu H, Davis RJ.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12046-51. doi: 10.1073/pnas.1209660109. Epub 2012 Jul 2.

2.

Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.

Gray-Schopfer VC, Karasarides M, Hayward R, Marais R.

Cancer Res. 2007 Jan 1;67(1):122-9. Erratum in: Cancer Res. 2007 Feb 15;67(4):1877.

3.

JNK2 is a positive regulator of the cJun transcription factor.

Jaeschke A, Karasarides M, Ventura JJ, Ehrhardt A, Zhang C, Flavell RA, Shokat KM, Davis RJ.

Mol Cell. 2006 Sep 15;23(6):899-911.

4.

Active Ras-induced effects on skeletal myoblast differentiation and apoptosis are independent of constitutive PI3-kinase activity.

Karasarides M, Dee K, Schulman D, Wolfman A, Weyman CM.

Cell Biol Int. 2006 Apr;30(4):308-18. Epub 2006 Feb 24.

PMID:
16503174
5.

ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis.

Mavria G, Vercoulen Y, Yeo M, Paterson H, Karasarides M, Marais R, Bird D, Marshall CJ.

Cancer Cell. 2006 Jan;9(1):33-44.

6.

The RAF proteins take centre stage.

Wellbrock C, Karasarides M, Marais R.

Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85. Review.

PMID:
15520807
7.

B-RAF is a therapeutic target in melanoma.

Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R.

Oncogene. 2004 Aug 19;23(37):6292-8.

PMID:
15208680
8.

V599EB-RAF is an oncogene in melanocytes.

Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R.

Cancer Res. 2004 Apr 1;64(7):2338-42.

9.

Supplemental Content

Loading ...
Support Center